Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects
暂无分享,去创建一个
[1] Itraconazole , 2020, Reactions Weekly.
[2] G. Thompson,et al. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation , 2018, Mycoses.
[3] I. Kerridge,et al. Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation , 2017, The Journal of antimicrobial chemotherapy.
[4] Alison M Semrad,et al. In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia , 2017, Antimicrobial Agents and Chemotherapy.
[5] A. Odermatt,et al. Inhibition of 11[beta]-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole , 2017 .
[6] A. Odermatt,et al. Inhibition of 11 b-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole , 2017 .
[7] R. Upton,et al. Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States , 2015, Antimicrobial Agents and Chemotherapy.
[8] D. Andes,et al. Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.
[9] P. Pappas,et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] MANUPAT LOHITNAVY,et al. Reduced oral itraconazole bioavailability by antacid suspension , 2005, Journal of clinical pharmacy and therapeutics.
[11] G. Drusano. How does a patient maximally benefit from anti-infective chemotherapy? , 2004, Clinical Infectious Diseases.
[12] M. Potter,et al. The Role of Itraconazole in Preventing and Treating Systemic Fungal Infections in Immunocompromised Patients , 2004, Acta Haematologica.
[13] W. Leisenring,et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.
[14] A. Peer,et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects , 2004, European Journal of Clinical Pharmacology.
[15] C. Hamilton,et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. , 2003, The Journal of antimicrobial chemotherapy.
[16] H. Prentice,et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] C. Leutner,et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.
[18] S. Sriwiriyajan,et al. Effect of omeprazole on the pharmacokinetics of itraconazole , 1998, European Journal of Clinical Pharmacology.
[19] J. Barone,et al. Food Interaction and Steady‐State Pharmacokinetics of Itraconazole Oral Solution in Healthy Volunteers , 1998, Pharmacotherapy.
[20] Y. Yazaki,et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole , 1998, Hematological oncology.
[21] M. Klausner,et al. Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers , 1997, Journal of clinical pharmacology.
[22] B. Gazzard,et al. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. , 1997, Journal of clinical pathology.
[23] S. Jaruratanasirikul,et al. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole , 1997, European Journal of Clinical Pharmacology.
[24] J. Perfect,et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. , 1994, The American journal of medicine.
[25] R. Yeates,et al. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. , 1994, Drugs under experimental and clinical research.
[26] Anosh Joseph,et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers , 1993, Antimicrobial Agents and Chemotherapy.
[27] J. Dunn,et al. High-dose itraconazole in the treatment of severe mycoses , 1991, Antimicrobial Agents and Chemotherapy.
[28] R. M. Tucker,et al. Adverse events associated with itraconazole in 189 patients on chronic therapy. , 1990, The Journal of antimicrobial chemotherapy.
[29] S. Clissold,et al. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.
[30] J. Graybill,et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.
[31] J. Enders,et al. Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.